Govt. of Himachal Pradesh took up initiative in early seventies to set up a CSIR lab to make prudential use of the natural resources of the region. After several levels of discussions a formal request was made by then Chief Minister of HP to Vice President, CSIR in 1982 for initiating the matter, and giving final shape to the proposal. The dream of HP government finally came true in 1983 when the foundation stone of this National lab was laid as CSIR Complex Palampur by Prof. Nurul Hasan, former Vice President of CSIR, with then Chief Minister of HP chairing the function.
Aerie Pharmaceuticals, Inc an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. RoclatanTM is a once-daily eye drop designed to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. It is a fixed dose combination of Aerie’s Rhopressa®, which is currently available in the United States, and the widely-prescribed PGA (prostaglandin analog) latanoprost. RoclatanTM successfully achieved its primary efficacy endpoint in two Phase 3 registration trials, named Mercury 1 and Mercury 2, and also achieved successful 12-month safety and efficacy results in Mercury 1, the results of which are included in the NDA submission.
